Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion Recommending The Approval Of Biogen's High-dose Regimen Of Nusinersen For 5q Spinal Muscular Atrophy. Final Decision Expected In January 2026

Author: Benzinga Newsdesk | November 17, 2025 06:02am

If adopted by the European Commission, the high dose regimen will be an additional dosing option to the already approved 12 mg low dose regimen.

Posted In: BIIB